HANSOH PHARMA (03692) announced that its self-developed Class 1 innovative drug, HS-10587 tablets, has obtained a clinical trial approval notice issued by the National Medical Products Administration (NMPA) of China. The drug is intended for clinical trials targeting advanced solid tumors with MTAP deletion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.